Hong Kong-based artificial intelligence (AI) drug discovery firm Insilico Medicine has raised $60 million in a Series D round of financing, less than one year after the completion of its previous Warburg Pincus-led investment at $255 million.
Insilico raised the fresh capital from a mix of new investors, including an unspecified asset management firm on the US West Coast and BHR Investment, as well as old investors, including Warburg Pincus, B Capital, Qiming Venture Partners, BOLD Capital Partners and Pavilion Capital. Insilico founder and CEO Alex Zhavoronkov also invested in the Series D round.